This section explains how to read clinical studies, trials, and statistics, including study design, bias, outcomes, funding disclosures, and how to judge the strength of health claims. This page lists all 63 ClinicalStudyConnect.com guides on the topic, each with its opening lines so you can pick the one that matches your question.
ClinicalStudyConnect.com is an independent publication. These guides are for education and do not replace care from a qualified professional.
Guides in this section
Dose-Response Relationships in Supplement Research: Why More Is Not Always Better
A dose-response relationship describes how the effect of a supplement or drug changes as the amount taken changes. In supplement research, this relationship is rarely a straight line. A low dose may do little, a moderate dose may show a measurable effect, and a higher dose may not add benefit at all.
The Placebo Effect in Supplement Research: What It Means for Interpreting Results
The placebo effect happens when a person feels or reports a change after taking a treatment that has no active ingredient. In supplement research, this matters because many symptoms researchers measure—like energy, mood, sleep quality, or pain—are self-reported and can shift just from expecting a benefit.
Bioavailability Studies: How Researchers Measure What Your Body Actually Absorbs
Bioavailability studies measure how much of a substance actually enters your bloodstream and becomes available for your body to use, not just how much you swallowed or applied.
Ingredient Evidence vs. Marketing Claims: A Consumer’s Guide
| September 2026 The supplement industry frequently uses phrases like "clinically proven," "backed by science," and "research shows" to market ingredients. But what do these terms actually mean?
Surrogate Endpoints Versus Outcomes People Feel: A Reader’s Test
Short answer: a clinical outcome is something a person in a study actually feels, does, or survives to experience — fewer symptoms, more mobility, a longer life. A surrogate endpoint is a stand-in measurement, usually a lab value or scan result, that a study uses instead because it shows up faster or is easier to track.
A Trial Reports a Composite Outcome: Which Event Drove the Result?
When a trial reports that a composite outcome was "reduced by 25%" or "occurred less often" in the treatment group, that single number can mean very different things depending on which of the combined events actually changed.
Trial Registration Changes: How to Compare the Original and Final Plan
A study's registration record is not fixed. Sponsors update it over the life of a trial, and the version showing today may not match what was filed before the trial started.
A Trial Has a Protocol but No Posted Results: How to Trace Its Status
If you found a registered trial with a full protocol — design, population, dosing, outcome measures — but no results posted, the short answer is: check three dates and one status field before assuming anything went wrong.
The Study Population Excludes Older Adults: What That Limits
If a study you are reading excluded people over a certain age, or excluded people with the health conditions you actually have, the results may not tell you much about what will happen to you. That is the short answer.
Trial Subgroup Claims in a Press Release: Matching the Headline to the Protocol
When a press release says a treatment "worked best" in a particular slice of a trial — women over 65, a specific genotype, patients with more severe symptoms at baseline — the headline is describing one piece of the study, not the whole result.
Primary Outcome Versus Secondary Outcome: Which Result Was the Trial Built to Test?
A trial can report ten different results, but only one of them was the result the trial was actually built, sized, and funded to answer. That result is the primary outcome .
Adverse Events Are Reported as a Table: What to Compare First
The short answer: Before you compare any percentages in an adverse event table, compare three things across the study groups. First, the number of participants who were actually assessed for harms in each group (the denominator). Second, the absolute count of participants affected in each group.
Per-Protocol Versus Intention-to-Treat Results: Two Views of One Trial
An intention-to-treat (ITT) result compares everyone who was randomized, counted in the group they were assigned to, whether or not they followed the plan. A per-protocol (PP) result compares only the participants who received their assigned treatment without major protocol deviations.
Missing Trial Data: Why Dropout Reasons Matter
Short answer: When people leave a clinical trial, their outcomes go unrecorded. Whether that gap distorts the result depends largely on why they left. If participants left for reasons unrelated to how they were doing, the remaining data may still give a fair comparison.
A Trial Is Funded by Its Manufacturer: What to Check Beyond the Disclosure
. Updated September 26, 2026. Picture a news story about a new study. Near the bottom, one line reads, "This trial was funded by the manufacturer." You wonder whether that changes how much to trust it. The short answer: a funding disclosure only tells you who paid.
Unpublished Trial Results: Finding the Registry and Reporting Gap
If a clinical trial has finished but you can't find published results, check its ClinicalTrials.gov record first. Search the trial by name, condition, or NCT number, then look at two dates: the Primary Completion Date and the Study Completion Date .
A Noninferiority Trial: What Its Margin Means for Patients
If you already know a noninferiority trial compares a new treatment to an existing one instead of a placebo, here's the part that actually determines whether a "noninferior" result means anything: the margin.
An Interim Trial Analysis: Why Early Results Can Change
An interim analysis is a planned look at a clinical trial's data before the study finishes enrolling or following participants. Researchers check it against rules set before the trial started.
Trial Adherence Is Low: How to Read the Treatment Actually Received
When trial adherence is low, check who was analyzed and which group each person was counted in. An analysis by assigned group answers what happened to people offered a treatment. It does not answer what happens when treatment is taken exactly as directed. Those are different questions. . Last updated: September 26, 2026.
An Open-Label Trial: What Participants and Researchers Knew
In an open-label trial, everyone involved — the person enrolled, the study team, and the doctors assessing outcomes — knows which treatment the participant is receiving. There is no placebo group hidden behind a code, and no blinding to break.
Blinded Outcome Assessment: Why It Matters Even Without a Blindfolded Patient
A clinical trial can be "blinded" in more than one place. Patients not knowing their treatment is only one form of blinding — and often the least important one for outcome accuracy. What matters just as much, and sometimes more, is whether the person scoring the results knows which group a participant was in.
Confidence Intervals in Trial Results: Range, Precision, and Uncertainty
A confidence interval is a range of numbers, not a single number. When a trial reports a result, it also reports a confidence interval — usually a 95% confidence interval — showing the range of values the true effect probably falls within. A narrow interval means the estimate is precise.
Trial Comparator Choice: Placebo, Usual Care, and Active Treatment
A comparator is whatever the control group in a clinical trial receives instead of the treatment being tested. Trials commonly use one of three comparator types: a placebo (an inactive substance or sham procedure), usual care (whatever a patient would normally receive outside the study), or an…
Absolute Versus Relative Risk in a Trial: Working Through the Same Numbers
Relative risk tells you how many times as likely an event was in one trial group compared with the other. Absolute risk tells you how many people actually had the event. The same result can be a big relative change and a small absolute change, so you need the baseline risk and the time period before judging it. .
Subgroup Findings: When a Difference May Be Chance
You read that a study "worked better in women" or "only helped people over 60." Should you trust that difference? Often the careful answer is: not yet.
Surrogate Outcomes in Trials: A Number Versus a Patient Benefit
A surrogate outcome is a measurement a trial uses in place of what patients care about most: how they feel, how well they function, or whether they live longer. A lab number or scan result can move in the right direction without proving that people are better off.
Trial Protocol Changes: Where to Find the Amendment Record
Say you or a family member enrolled in a clinical trial six months ago, or you've been following a trial's registration page while deciding whether to join. Then you notice something looks different: the number of participants has changed, an outcome measure has been reworded, or the study's estimated end date has moved.
Trial Adverse Events: Denominators, Severity, and Follow-Up
When a clinical trial reports that "12% of participants had a side effect," that number is only useful if you know three things: what group is in the denominator, how severe the events were, and how long participants were tracked.
Differential Dropout in Clinical Trials: When One Group Loses More Participants Than the Other
Two trials can report the exact same overall dropout rate and mean very different things. What matters just as much as the total percentage of people who left a study is whether they left evenly from both groups — or mostly from one.
A Study Has Many Outcomes: Why the Primary One Matters
You're reading about a clinical study — maybe one a product cites, maybe one a doctor mentioned, maybe one you found searching for a condition. The summary lists several things the study measured, and one of them sounds impressive.
A Clinical Study Abstract: What to Check in the Full Report
A clinical study abstract is written to compress months or years of research into a few hundred words. That compression means the abstract usually leaves out the details that determine whether a result actually applies to a given situation. The full report is where those details live.
Clinical Trial Randomization: What It Balances and What It Cannot
Randomization is the step in a clinical trial where participants are assigned to a study group — such as a treatment group or a comparison group — by chance rather than by choice.
Trial Registration Dates: Was the Main Outcome Named Before Results
To check whether a trial's main outcome was named before results existed, compare the date the trial was registered with the date it started, then compare the primary outcome in the registry with the one in the published paper.
Noninferiority Trials: When a Study Is Asking Whether an Option Is Not Much Worse
If you've come across a clinical study and the summary says something like "Drug B was not inferior to Drug A," you may assume the researchers just failed to show Drug B was better. That's usually the wrong reading. Many of these studies were never designed to test which option works better at all.
Intention-to-Treat Analysis: Why Trial Results Often Keep People in Their Original Groups
Disclosure: if you buy through a link on this page, we may earn a commission. It does not change what we write or how we assess a product.
Preprints and Peer Review: What Has Been Checked and What Has Not
When a study claim is shared online, one of the first things worth checking is whether it comes from a preprint or a peer-reviewed article.
Heterogeneity in a Meta-Analysis: Why Study Results May Not Agree
When a meta-analysis combines results from several studies, the headline number — the "pooled effect" — can hide real disagreement between the studies feeding into it. That disagreement is called heterogeneity, and checking for it is one of the most important steps in deciding how much weight a meta-analysis result deserves.
Relative Risk and Absolute Risk: How the Same Result Can Sound Different
A headline claiming something "cuts your risk by 50%" is reporting relative risk — how much bigger or smaller one group's risk is compared to another's. It says nothing about absolute risk , the actual chance of the event happening at all.
Industry Funding and Author Conflicts: How to Read the Disclosure Section
A study's disclosure section lists who funded the research, what role that funder played, and whether the authors have financial ties to it. Reading it well means recording those facts without deciding, on that basis alone, that the study is trustworthy or worthless.
Number Needed to Treat: A Useful Summary With Important Limits
Number needed to treat, or NNT, is the average number of people who would need to receive a treatment for one additional person to get the specific benefit a study measured, compared with not receiving it, over a set period of time.
Blinding in Clinical Trials: Who Knew What, and When?
Blinding in clinical trials means keeping study participants, clinicians, outcome assessors, or data analysts unaware of which treatment a person received. It matters because that knowledge can influence behavior, judgment, and measurement.
Randomization and Allocation Concealment: Two Different Protections Against Bias
When a study says participants were "randomized," that word is doing less work than most readers assume. Randomization actually involves two separate protections against bias: generating a random sequence for assigning participants to groups, and concealing that sequence from everyone involved…
Missing Data and Participant Dropout: Questions Every Trial Summary Should Answer
Missing data and participant dropout happen when people leave a clinical trial before the study ends, and if the missing group differs from the group that stayed, the reported result can be skewed without anyone stating it outright.
Subgroup Analyses: When a Promising Result Needs Extra Caution
When researchers run a clinical study, they usually report one main result: how the whole group of participants responded to a treatment or ingredient. A subgroup analysis looks deeper.
Surrogate Endpoints: When a Biomarker Is Not the Outcome Readers Care About
A surrogate endpoint is a substitute measurement — often a lab value, scan result, or biomarker — that researchers use instead of directly measuring how a patient feels, functions, or survives. It only counts as real evidence of benefit once separate research confirms the measurement reliably predicts that clinical outcome.
Confidence Intervals: The Range Around a Study Estimate
A confidence interval is a range of numbers, not one single number, that shows how precise a study's estimate is. When a result is reported as "2 to 8," that whole range — not just the number in the headline — is the actual finding worth reading. Researchers almost never test an entire population.
Primary and Secondary Outcomes: How to Find What a Trial Was Built to Test
A clinical trial’s primary outcome is the single main question the study was designed and sized to answer; secondary outcomes are additional measures collected alongside it; exploratory outcomes are collected mainly to suggest ideas for future research.
Trial Protocol Amendments: What Changed, When, and Why It Matters
A clinical trial protocol amendment is a formal, dated change to a study's written plan — who can join, what gets measured, or how long it runs.
Clinical Trial Phases Explained: From Phase I Safety to Phase IV Post-Market Surveillance
Disclosure: if you buy through a link on this page, we may earn a commission. It does not change what we write or how we assess a product. Clinical trials progress through four main phases before a drug or treatment can reach the market, and a fifth phase of monitoring afterward.
Animal Studies vs Human Trials: The Translation Gap
Animal studies and in-vitro experiments are essential early steps in research, but they cannot predict how a treatment will actually behave in the human body.
Publication Bias: Why Negative Results Rarely Get Published and Why That Matters
Publication bias happens when studies with positive or exciting results are more likely to get published than studies that find no effect or a negative effect. This matters because the medical literature you can search on sites like PubMed ends up skewed.
Sample Size and Statistical Power: Why Small Studies Can Mislead
Sample size is the number of people enrolled in a study. Statistical power is a study's ability to detect a real effect if one truly exists.
Understanding P-Values and Statistical Significance in Health Research
A p-value is a number that helps researchers decide if a study result probably happened by chance or reflects a real effect. A small p-value (usually below 0.05) means the result is unlikely to be random noise. A p-value does not tell you how big, how important, or how helpful an effect actually is.
Meta-Analyses and Systematic Reviews: How Researchers Combine Evidence From Multiple Studies
A systematic review is a structured search that finds and evaluates every study that fits a specific research question. A meta-analysis goes one step further: it uses statistics to combine the results of similar studies into one overall number.
Observational Studies: Cohort, Case-Control and Cross-Sectional Research Compared
Cohort, case-control, and cross-sectional studies are the three main types of observational research. They all study people as they live their normal lives, without assigning any treatment.
Randomized Controlled Trials Explained: The Gold Standard and Its Real Limitations
A randomized controlled trial (RCT) is a research study where people are randomly assigned to either a treatment group or a comparison group, so researchers can measure the treatment's real effect.
Clinical Study Safety Data: Adverse Events, Limitations, and What to Watch For
| September 2026 Safety data in clinical studies tells you what happened to participants beyond the intended benefit — side effects, adverse events, interactions, and tolerability.
Understanding Emerging Research: Preliminary Findings and What They Mean
| September 2026 Emerging research is the frontier where new discoveries are made — and where hype is most likely to outrun evidence.
Research Funding, Conflicts of Interest, and Study Independence
| September 2026 Who pays for research affects what gets studied, how results are reported, and which findings get published.
Study Populations, Dosing, and Outcomes: What the Details Tell You
| September 2026 A clinical study's findings only apply to the people it studied, at the dose it tested, for the duration it ran. These details — study population, dosing, and outcome measures — are often the difference between evidence that is relevant to you and evidence that is not.
Evaluating Evidence Quality: How to Assess the Strength of Research Findings
| September 2026 A single clinical study — no matter how promising — is not proof. The strength of evidence behind a health claim depends on how many studies exist, how well they were designed, whether they have been replicated, and whether the results are consistent.
Understanding Clinical Study Design: RCTs, Observational Studies, and More
| September 2026 Not all clinical studies are created equal. The type of study design determines what conclusions can be drawn from the results.
How to Read a Clinical Study: A Plain-Language Guide
| September 2026 Clinical studies are the foundation of evidence-based health decisions, but most are written for other scientists.